Skip to Content
Merck

A3160

Acetylsalicylic acid

analytical standard

Synonym(s):

2-Acetoxybenzoic acid, O-Acetylsalicylic acid, ASA, Aspirin

Slide 1 of 2
Sign In to View Organizational & Contract Pricing

Select a Size

1 VIAL

$286.00

$286.00

Check Cart for Availability
Request a Bulk Order

About This Item

Linear Formula:
2-(CH3CO2)C6H4CO2H
CAS Number:
50-78-2
Molecular Weight:
180.16
Beilstein:
779271
EC Number:
200-064-1
MDL number:
MFCD00002430
UNSPSC Code:
12352106
PubChem Substance ID:
24890723
NACRES:
NA.21

Key Documents

View All Documentation

Skip To

Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

grade

analytical standard

Quality Level

200

form

powder

packaging

vial of 500 mg

technique(s)

HPLC: suitable
gas chromatography (GC): suitable

mp

134-136 °C (lit.)

application(s)

forensics and toxicology
pharmaceutical
veterinary

SMILES string

CC(=O)Oc1ccccc1C(O)=O

InChI

1S/C9H8O4/c1-6(10)13-8-5-3-2-4-7(8)9(11)12/h2-5H,1H3,(H,11,12)

InChI key

BSYNRYMUTXBXSQ-UHFFFAOYSA-N

Gene Information

human ... ITGA2B(3674), PTGS1(5742), PTGS2(5743)

Looking for similar products? Visit Product Comparison Guide

Related Categories

Compare Similar Items

View Full Comparison

Show Differences

1 of 4

This Item
A0200000A5376A2093
Acetylsalicylic acid analytical standard

Sigma-Aldrich

A3160

Acetylsalicylic acid

Acetylsalicylic acid European Pharmacopoeia (EP) Reference Standard

A0200000

Acetylsalicylic acid

Acetylsalicylic acid ≥99.0%

Sigma-Aldrich

A5376

Acetylsalicylic acid

Aspirin meets USP testing specifications

Sigma-Aldrich

A2093

Aspirin

Gene Information

human ... ITGA2B(3674), PTGS1(5742), PTGS2(5743)

Gene Information

human ... PTGS1(5742), PTGS2(5743)

Gene Information

human ... ITGA2B(3674), ITGB3(3690), PTGS1(5742), PTGS2(5743)

Gene Information

human ... ITGA2B(3674), PTGS1(5742), PTGS2(5743)

Quality Level

200

Quality Level

-

Quality Level

200

Quality Level

200

form

powder

form

-

form

powder

form

powder or crystals

mp

134-136 °C (lit.)

mp

134-136 °C (lit.)

mp

134-136 °C (lit.)

mp

134-136 °C (lit.)

grade

analytical standard

grade

pharmaceutical primary standard

grade

-

grade

-

packaging

vial of 500 mg

packaging

-

packaging

-

packaging

-

Biochem/physiol Actions

Blocks the production of prostaglandins by inhibiting cyclooxygenase (prostaglandin H synthase), with greater selectivity toward the COX-1 isoform. The antithrombotic effect is due to the inhibition of COX-1 in platelets that blocks thromboxane production and platelet aggregation. Chemopreventive against colorectal and other solid tumors.

Packaging

Supplied in amber screw-cap vials

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H302

Precautionary Statements

P264 - P270 - P301 + P312 - P501

Hazard Classifications

Acute Tox. 4 Oral

Storage Class Code

11 - Combustible Solids

WGK

WGK 1

Flash Point(F)

482.0 °F

Flash Point(C)

250 °C

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000398362
0000342719
SLCQ5262
SLCQ5262
0000398362

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Niels Hulsman et al.
Journal of medicinal chemistry, 50(10), 2424-2431 (2007-04-20)
Hybrid drug 1 (NO-ASA) continues to attract intense research from chemists and biologists alike. It consists of ASA and a -ONO2 group connected through a spacer and is in preclinical development as an antitumor drug. We report that, contrary to
Connie N Hess et al.
Journal of the American College of Cardiology, 66(7), 777-787 (2015-08-14)
Bleeding limits anticoagulant treatment in patients with acute coronary syndromes (ACS). We investigated whether background concomitant antiplatelet therapy influences the effects of apixaban after ACS. This study examined high-risk ACS patients who were treated with aspirin or aspirin plus clopidogrel
Andrew O Maree et al.
Journal of the American College of Cardiology, 46(7), 1258-1263 (2005-10-04)
We investigated whether use of low-dose enteric-coated (EC) aspirin for secondary prevention of cardiovascular events has sufficient bioavailability to achieve complete platelet cyclooxygenase (COX) inhibition in all individuals. Aspirin reduces cardiovascular morbidity and mortality in patients with pre-existing vascular disease;
Christina Perneby et al.
Thrombosis and haemostasis, 95(4), 652-658 (2006-04-08)
Aspirin is widely used, but dosages in different clinical situations and the possible importance of "aspirin resistance" are debated. We performed an open cross-over study comparing no treatment (baseline) with three aspirin dosage regimens--37.5 mg/day for 10 days, 320 mg/day
A O Maree et al.
Journal of thrombosis and haemostasis : JTH, 3(10), 2340-2345 (2005-09-10)
Aspirin (acetylsalicylic acid) irreversibly inhibits platelet cyclooxygenase (COX)-1, the enzyme that converts arachidonic acid (AA) to the potent platelet agonist thromboxane (TX) A2. Despite clear benefit from aspirin in patients with cardiovascular disease (CAD), evidence of heterogeneity in the way
View All Related Papers

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service